Breaking News, Promotions & Moves

BASi Announces New CCO

Mr. Joe Flynn has over 25 years of strategic and operational experience focusing on pharmaceutical research and development

Bioanalytical Systems (BASi) has appointed Joe Flynn as chief commercial officer, effective as of February 21, 2019. Mr. Flynn will be responsible for leading sales and marketing efforts across BASi’s three sites located in West Lafayette and Evansville, Indiana, and St. Louis, Missouri.

Mr. Flynn has over 25 years of strategic and operational experience focusing on pharmaceutical research and development. Most recently, he served as chief commercial officer and executive vice president of Seventh Wave Laboratories. Mr. Flynn joined BASi in July of last year when BASi acquired the operations of Seventh Wave in order to provide broader solutions and greater scientific expertise to its clients.

“I have great confidence in Joe and his ability to shape our commercial engine,” said Robert Leasure, Jr., BASi’s president and chief executive officer. “The team Joe has in place is solidly positioned to help drive our internal growth objectives and support any external opportunities we have in the future. Joe will play a vital role on our leadership team and brings a valuable combination of laboratory experience, industry knowledge, and commercial leadership. His appointment fills one more critical position towards our Company’s growth and ability to support our clients.”

Prior to his tenure at Seventh Wave Laboratories, Mr. Flynn was a global vice president of sales and client services for multiple divisions of Covance Laboratories. Prior to Covance, he held operational roles at PPD Inc. and ABC Laboratories (now Eurofins). 

“I am enthusiastic about the opportunities before us, and proud to be a part of this team. Our position—being small enough to be responsive but big enough to deliver—is already resonating with clients. We have good momentum and are building backlog and serving our loyal clients, while layering in new clients every day. With modest enhancements to our commercial engine, we have a great opportunity to differentiate our integrated offerings and help our clients exceed their goals.” said Mr. Flynn.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters